Based on observations, several cases of Needle Stick Injury (NSI) were found in nurses in the inpatient unit of RSUD H. Abdul Manap Jambi City during the vulnerable years 2022 to 2024. The risk of Needle Stick Injury (NSI) can cause infections such as HBV (Hepatitis B), HCV (Hepatitis C), and HIV (Human Immunodeficiency Virus). The purpose of this study was to determine the factors associated with the incidence of NSI in nurses in the inpatient unit of RSUD H. Abdul Manap Jambi City. This study is a quantitative study using an analytic survey with a cross sectional approach. The instruments used were structured questionnaires and observation sheets that were prepared based on literature review and had been tested for validity and reliability. This instrument selection was carried out to obtain data in accordance with the research objectives. The population in this study were 78 executive nurses in the inpatient unit with sampling using sampling techniques (total sampling). Data analysis used the chi-squre test to identify the determinants of the incidence of NSI. The results of this study showed the incidence of Needle Stick Injury (NSI) in nurses in the inpatient unit of RSUD H. Abdul Manap Jambi City who had experienced (43.6%) and who had not (56.4%). There is a relationship between K3 training and the incidence of Needle Stick Injury (NSI) (p = 0.000), work shifts with the incidence of NSI (p = 0.000), and there is no relationship between the use of PPE with the incidence of NSI (p = 0.278). It is concluded that there is a relationship between the incidence of Needle Stick Injury (NSI) in nurses at the inpatient unit of RSUD H. Abdul Manap Jambi City, namely K3 training and work shifts. While those that are not related, namely the use of PPE because it is not statistically significant.

Although the hematopoietic cell transplantation (HCT)-comorbidity index (HCT-CI) score is associated with an increased risk of mortality after allogeneic HCT, it remains unclear how pre-HCT liver dysfunction affects clinical outcomes. We retrospectively compared clinical HCT outcomes among four groups stratified according to the presence of HCT-CI liver and other organ scores, using a Japan transplant registry database between 2010 and 2020. Of the 14235 recipients, 1527 tested positive for an HCT-CI liver score including HBV or HCV hepatitis (n = 503). The 5-year overall survival (OS) was significantly lower in the HCT-CI liver(+) other(+) and HCT-CI liver(-) other(+) groups compared to the HCT-CI liver(+) other(-) and HCT-CI liver(-) other(-) groups [49.9% vs. 59% vs. 66.5% vs. 68.3%, p < 0.001]. A multivariate analysis showed that both the HCT-CI liver(+) other(+) [HR 1.62, p < 0.001] and HCT-CI liver(-) other(+) groups [HR 1.21, p < 0.001] were significantly associated with inferior OS. Similarly, both the HCT-CI liver(+) other(+) [HR 1.89, p < 0.001] and liver(-) other(+) groups [HR 1.26, p < 0.001] were significantly associated with an increased risk of NRM. On the other hand, the HCT-CI liver(+) other(-) group was not associated with either OS or NRM. Separately analyzing the subcohorts with or without HCT-CI other scores, the presence of an HCT-CI liver score alone did not affect survival, while the co-presence of pretransplant liver dysfunction seemed to synergistically increase the adverse impact on OS and NRM among recipients with other organ comorbidities. Further studies will be needed to identify optimal strategies for recipients with pretransplant liver dysfunction.

Background/Objectives: The issue of HCC recurrence in patients with liver cirrhosis and chronic HCV infection after DAA treatment as well as the issue of de novo HCC in individuals with chronic HCV hepatitis treated with DAA is of great importance. In this review, the two important aspects are discussed and, finally, an algorithm for approaching the patient with HCC and chronic HCV infection is proposed. Methods: A literature search of the two databases (PubMed and Scopus) was conducted using the terms 'chronic hepatitis C' and/or 'liver cirrhosis' and 'hepatocellular carcinoma', from database inception to December 2024. Results: Thirty-one studies have examined the risk of HCC recurrence. Most of these studies conclude that DAA treatment reduces the risk of HCC recurrence compared to patients who did not receive DAA. There are considerable differences across various world regions. These variations may arise from: differences in genotypes, baseline characteristics of the populations, variability in DAA treatment protocols, and differences in follow-up intervals. Eleven studies that investigated the issue of de novo HCC after DAA were reviewed, of which two included historical cohorts of untreated patients. Conclusions: The conclusion is that these patients present a low or equal risk of HCC incidence compared to untreated patients, and the risk factors for HCC are: lower platelet number, impaired liver function, nonresponse to DAA. Most patients with chronic hepatitis C and HCC should receive DAAs, except for those in BCLC stage D, but we must emphasize that timing of intervention is crucial and it is very important to evaluate possible drug interactions.

This work examined the diagnostic role of biomarkers -APRI, alpha-fetoprotein–AFP and gammaglutamine transpeptidase–GGTP before and after antiviral therapy in patients with different degrees of liver fibrosis. At the same time, there was a decrease in these indicators after treatment, which indicates a reverse development of liver fibrosis after specific therapy.During therapy, a significant decrease in APRI from 0.67 to 0.33 (p&lt;0.05), AFP from 4.82 to 1.77 (p&lt;0.01) and GGTP from 42.4 to 26.8 was established (p&lt;0.05). Thus, APRI, AFP and GGTP indicators can be used as dynamic markers for assessing the antifibroticeffect of etiotropic therapy for hepatitis C

Chronic viral hepatitis B (HBV) and C (HCV) infection could negatively affect outcomes of non-hepatic solid organ transplantations due to the risk of viral reactivation in the presence of immunosuppression. This study aimed to determine post-transplant outcomes in patients with HBV or HCV positivity receiving non-hepatic solid-state organ transplant. Data was collected from the Scientific Registry of Transplant Recipients (SRTR) 2006-2021 for patients (≥18) who received a lung, heart, or kidney single organ transplant in the U.S. Hepatitis C positivity (HCV+) was determined as positive HCV Ab and hepatitis B positivity (HBV+) as positive HBsAg. We included N = 30,872 lung, N = 36,990 heart and N = 280,162 kidney transplant recipients. The prevalence of HBV+ was 1.3% in lung, 1.5% in heart and 1.7% in kidney patients, HCV+ was 2.2%, 2.2% and 5.0%, respectively. Post-transplant survival of patients with vs. without HBV+ was similar in all solid organ transplants (all p > .05). Similarly, there was no difference in post-transplant survival between lung transplant recipients with vs. without anti-HCV (all p > .05). Heart transplant recipients with HCV+ had higher crude post-transplant mortality (all p < .01). Similarly, there was higher post-transplant mortality in kidney transplant recipients with HCV+ (1-year: 6% vs. 3%; 5-year: 21% vs. 13%; 10-year: 47% vs. 31%; all p < .0001). In multivariate analysis controlling for confounders, only the association of HCV+ with higher post-kidney transplant mortality remained significant: adjusted hazard ratio (aHR) (95% CI) = 1.16 (1.12-1.20), p < .0001. There was no association of viral hepatitis seropositivity with the risk of graft failure in all groups (p > .05). In most cases, the presence of HBV or HCV serologies is not associated with adverse post-transplant outcomes in non-hepatic solid organ transplants. However, kidney transplant recipients who are positive for HCV serology have an increased risk for post-transplant mortality.

BackgroundHepatitis C virus (HCV) infection is the most challenging public health problem in Egypt where the prevalence is the highest in the world. Intrafamilial transmission of hepatitis C occurring between patients infected with HCV and their household members sharing the same house and living conditions. Preventive measures of hepatitis C are considered the first line of defense against HCV infection.Aimassess the intrafamilial transmission risk factors and preventive measures followed by household contacts of hepatitis C patients.DesignA descriptive cross sectional research design was utilized.SettingThe study was conducted at outpatient clinics of Liver Institute at Kafer-Elsheikh Governorate.SampleA simple random sample of 365 household contacts of hepatitis C patients was recruited for the current study.ToolData was collected through one tool: A structured Interviewing Questionnaire for household contacts of hepatitis C patients which included three parts; part I-(a) Demographic data, (b) Medical history of household contacts, Part II (a) Household contacts knowledge about HCV (b) Hepatitis C risk factors, Part III: Preventive measures followed by household contact of hepatitis C patient: This part is self-reported practices.ResultsThe study revealed that;56.7% of household contacts were males, 72.1% of them were living in rural areas, 75.60% were married, with a mean age ±SD 36.73±9.18 years old.44.1% obtained secondary education, 30.7% were employees, among this group hypertension and diabetes were the main chronic illness. 49.90% had moderate level of general knowledge about HCV infection, 71.50% had low level of knowledge about hepatitis C risk factors and 90.00% had a low level of preventive measures (self-reported practices) regarding HCV. There was no correlation between household contacts knowledge about HCV risk factors and their preventive measures(r=0.031 andP=0.549).ConclusionAlmost half of household contacts mentioned that they knew intrafamilial risk factors while about half of this group have a misconception about intrafamilial risk factors, while majority of them stated that they knew sharing scissors and clippers as the main intrafamilial risk factors and less than one-fourth of them knew direct contact with infected blood and sharing of special equitoothbrushesth brushes. Household contacts applied some preventive measures such as; Cover the wound with a piece of cloth or gauze, disinfect the site with alcohol or antiseptic solution and frequent and proper hand washing.RecommendationsRoutine health assessment of household contacts knowledge regarding intrafamilial risk factors and preventive measures therefore health education sessions should be conducted to raise their awareness regarding HCV infection and further research should be conducted on larger samples of contacts.

Routinely collected and linked healthcare administrative datasets could be used to monitor mortality among people with hepatitis B (HBV) and C (HCV). This study aimed to evaluate the concordance in records of liver‐related mortality among people with an HBV or HCV notification, between data on hospitalization for end‐stage liver disease (ESLD) and death certificates. In New South Wales, Australia, HBV and HCV notifications (1993–2017) were linked to hospital admissions (2001–2018), all‐cause mortality (1993–2018) and cause‐specific mortality (1993–2016) datasets. Hospitalization for ESLD was defined as a first‐time hospital admission due to decompensated cirrhosis (DC) or hepatocellular carcinoma (HCC). Consistency of liver death definition of mortality following hospitalization for ESLD was compared with two death certificate‐based definitions of liver deaths coded among primary and secondary cause‐specific mortality data, including ESLD‐related (deaths due to DC and HCC) and all‐liver deaths (ESLD‐related and other liver‐related causes). Of 63,292 and 107,430 individuals with an HBV and HCV notification, there were 4478 (2.6%) post‐ESLD hospitalization deaths, 5572 (3.3%) death certificate liver disease deaths and 2910 (1.7%) death certificate ESLD deaths. Between 2001 and 2016, among HBV post‐ESLD hospitalization deaths (n = 891), 63% (562) had death certificate ESLD recorded, and 83% (741) had death certificate liver disease recorded. Between 2001 and 2016, among HCV post‐ESLD hospitalization deaths (n = 3587), 58% (2082) had death certificate ESLD recorded, and 87% (3135) had death certificate liver disease recorded. At least one‐third of death certificates with DC and HCC as cause of death had no mention of HBV, HCV or viral hepatitis. Our study identified limitations in estimating and tracking HBV and HCV liver disease mortality using death certificate‐based data only. The optimum data for this purpose is either ESLD hospitalisations with vital status information or a combination of these with cause‐specific death certificate data.

In this work, we analyze a viral hepatitis C model. This epidemic remains a major problem for global public health, in all communities, despite the efforts made. The model is analyzed using the stability theory of systems of nonlinear differential equations. Based on the results of the analysis, the proposed model has two equilibrium points: a disease-free equilibrium point E0 and an endemic equilibrium point E∗. We investigate the existence of equilibrium point of the model. Furthermore, based on the indirect Lyapunov method, we study the local stability of each equilibrium point of the model. Moreover, by constructing the appropriate Lyapunov function and by using LaSalle invariance principle, we get some information on the global stability of equilibrium points under certain conditions. The basic reproduction number R0 is calculated using the Next Generation method. The positivity of the solutions and their bornitude have been proven, the existence of the solutions has also been proven. Optimal control of the system was studied by proposing three types of intervention: awareness program, early detection, isolation and treatment. The maximum principle of Pontryagin was used to characterize the optimal controls found. Numerical simulations were carried out with a finite numerical difference diagram and using MATLAB to confirm acquired results.

Aim: The aim of this study is to assess the evolution of Fibromax® parameters (fibrosis, inflammation, steatosis, steatohepatitis) in patients with chronic HCV hepatitis at one year after sustained virologic response (SVR) achieved by direct acting antiviral agents (DAA). Methods: This is a retrospective observational trial including 73 patients with chronic HCV hepatitis, who obtained sustained virologic response under ombitasvir/paritaprevir/ritonavir and dasabuvir, ledipasvir/sofosbuvir or sofosbuvir/velpatasvir. All the patients were evaluated by Fibromax before the initiation of therapy and at 12 months after SVR. Results and Conclusion: The study included 42 women (57.53%) and 31 men (42.46%), without significant difference in mean age or BMI. We found a higher prevalence of patients with minimal or moderate fibrosis (F1, F2), compared to patients with advanced fibrosis (F3) (63.01% versus 10.95%). At one year follow-up, we found an increased number of patients in the lower levels of fibrosis, inflammation and NASH, with a relatively constant distribution of patients regarding steatosis. Necro-inflammatory activity was significantly diminished, with 58 patients in the no to minimal activity, compared to 37 patients before antiviral therapy. More patients presented N0 and N1 degree of NASH at follow-up than before therapy (63 patients versus 42 patients, p= 0.02). The mean values of Fibrotest (p= 0.03), ActiTest (p&lt;0.01) and NashTest (p=0.02) decreased significantly. The mean value of Steatotest also decreased, but without statistical significance (p=0.12).

In Japanese hospitals, patients undergoing invasive procedures or surgery are screened for anti-HCV antibodies; however, the majority of possible HCV careers are not referred to hepatologists. In addition to the conventional alert email system, a hepatologist extracted monthly lists of anti-HCV-antibody-positive patients who had been tested two months previously and checked medical records to determine whether the doctors who ordered the tests had properly dealt with the positive results. If the doctors had not yet properly followed up, the hepatologist would send emails to both the doctor and a medical clerk to inform them to conduct an HCV-RNA test and to refer HCV-RNA-positive patients to hepatologists. In total, 130 patients managed in the pre-intervention period and 151 patients managed in the post-intervention period were included in this study. The number of anti-HCV-positive patients whose results were not properly handled showed a significant decrease after the introduction of the double alert system (p = 0.034). Among patients undergoing screening anti-HCV antibody testing, a significant number of patients with probable chronic HCV hepatitis were overlooked by the email alert system and their results were not properly handled. The double alert system was useful for reducing the number of positive anti-HCV antibody patients whose results were not properly handled.

Chronic Hepatitis C (CHC) is a substantial global public health issue with significant variation between countries because of the genotypic differences. A sustained viral response (SVR) is essential to reduce the complications associated with CHC and can be achieved in most patients via direct-acting antivirals (DAAs). The present study aimed at determining the genotype distribution in patients with CHC in our region and the SVR in DAA therapy patients. The study was conducted retrospectively on 272 patients treated with DAA between September 2016 and 2021. Data including demographic and clinical characteristics of the patients (HCV RNA level, genotype, hepatitis B and HIV serology, cirrhosis and decompensation, presence of hepatocellular cancer, degree of hepatosteatosis, previous anti-HCV treatment experience, comorbidities) were recorded. The study's primary endpoint was to determine the SVR at week 24. Genotype 1 was the most common genotype (94.5%), with genotype 1b accounting for most patients (78%) among those. It was observed that the patients received Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir (OPRD) (47%), Ledipasvir/sofosbuvir (LDS) (38%), and Glecaprevir/pibrentasvir (GCP) (15%) as DAA treatment. SVR was observed in 92% (223) of the 240 patients at the end of 24 weeks. SVR-24 was significantly higher in the patient group with serum HCV RNA level ≤ 852.533 (p=0.002), in the hypertensive group (p=0.018), and without the psychiatric disease group (p<0.001). A high rate of SVR-24 was achieved by DAAs in CHC patients, most of whom were genotype 1 in the Western Black Sea Region, Turkey. Also, high viral load, hypertension, and psychiatric disease affected SVR-24, and clinical factors, such as cirrhosis, cirrhosis complications, hepatosteatosis, and other comorbidities did not.

Introduction: Acute hepatitis C (HCV) infection is rising in intravenous drug users/non-monogamy. Isoniazid (INH), commonly used for tuberculosis, may cause idiosyncratic drug-induced liver injury (DILI). Acute HCV infection was reported in 1.5% of suspected DILI. We here report a case of acute HCV infection for suspicious INH hepatitis in a patient with controlled human immunodeficiency virus (HIV) infection on antiretroviral therapy (ART). Case Description/Methods: A 54 years-old Caucasian male was admitted for several days of fatigue/nausea/abdominal pain with elevated ALT/AST at 179/93. He has a history of controlled HIV infection on dolutegravir/tenofovir/emtricitabine, non-monogamy (men having sex with men), marijuana/herbal use, and latent tuberculosis (with a normal liver test/negative HCV antibody) treated with INH for 3 months. Serology for acute hepatitis A, B, C infection, other work-ups, and abdominal ultrasound/CT were negative. INH rather than ART/herbals was suspected as the possible culprit for hepatotoxicity and was continued due to ALT < 5 times upper normal limit. Patient was discharged after a negative esophagogastroduodenoscopy and symptomatic improvement. He presented again 2 days later with ALT/AST of 287/153 then to 984/388 on the 9th day after INH cessation. Total bilirubin and INR had remained normal with minimally elevated ALP. HCV RNA was detected at 16.5 million IU/ml. A liver biopsy was performed for rising liver enzymes and excluding autoimmune hepatitis. Moderate portal/lobular inflammation with abundant hepatocyte apoptosis and mild intra-canalicular cholestasis without autoimmune hepatitis was reported, suggesting possible DILI with viral hepatitis per pathologist. However, with a strong competing diagnosis of acute HCV hepatitis, persistently rising ALT/AST despite cessation of INH, and only possible causality score for INH-DILI, the suspected INH hepatitis was adjudicated as acute HCV infection. Sofosbuvir-velpatasvir treatment was initiated with rapid normalization of ALT/AST and decreasing HCV RNA. Discussion: This is the first reported case of acute HCV infection for suspected INH hepatitis in a patient with controlled HIV infection on ART. The case emphasizes the importance of early HCV RNA testing for diagnosing/excluding acute HCV infection in suspicious DILI due to delayed seroconversion of HCV antibody. Prompt treatment with highly potent antiviral agents leads to eradication of HCV with potential public health benefit.

Background: Pulse oximetry with oxygen saturation (SpO2) ≤96% is recommended as a screening test to identify patients (pts) with severe hepatopulmonary syndrome (HPS) to be eligible for MELD exceptions. However, diagnosis of milder forms requires contrast-enhanced echocardiography (CE-TTE) and arterial blood gas (ABG). Goals: 1) To investigate the prevalence of intrapulmonary vascular dilatations (IPVD) and HPS in pts with cirrhosis evaluated for liver transplantation (OLT) and 2) To compare the results of SpO2 with ABG measurements. Methods: The study included 972 consecutive pts (2013-2021) who completed pre-OLT evaluation including CE-TTE, SpO2 and ABG. IPVD was defined as the appearance of microbubbles in the left heart within 3-5 cardiac cycles and HPS by an alveolar arterial O2 gradient ≥ 15 mm Hg or ≥ 20 if age > 64 and absence of pulmonary chronic diseases. HPS was considered as mild, moderate or severe according to PaO2 (>80, 60-80 and <60 respectively). Results: The prevalence of IPVD was 15.4% (150/972) and of HPS 7.8% (76/972). Age of pts with HPS was 47±3 years (57% males) and MELD-Na 17± 1.HCV, alcoholism and autoimmune hepatitis were the most frequent etiologies of cirrhosis (22% each). Among pts with HPS 59 (78%) were mild (PaO2 108 ±22), 13 (17%) moderate (73 ±4) and 4 severe (55.5±3). SpO2 was ≤96% in 26% (20/76), 15% in mild (9/59), 54% in moderate (8/13) and 100% in severe (4/4) HPS. Unexpectedly, of 20 pts with Spo2 ≤96% only 4 had PaO2 <60 mmHg. Conclusions: Universal testing with CE-TTE followed by ABG in patients with cirrhosis evaluated for OLT resulted in a lower prevalence than reported of HPS, most likely due to the preponderance of mild clinical forms with normal SpO2. Using the recommended cut-off value of Spo2 ≤96% we found a poor correlation between pulse oximetry and ABG measurement.

Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey

Liver cancer is a typical malignant tumor and the fourth most typical cancer in the Earth. Clinically, more than 90% of patients with primary liver cancer are caused by hepatocellular carcinoma. Epidemiological and experimental data show that human infection with HBV and HCV hepatitis virus is firmly connected with the occurrence of liver cancer. In the past 20 years, the level of diagnosis and cure of liver cancer in China has been greatly improved, but little progress has been made in the study of liver cancer markers. For then, with the understanding of Wnt signal transduction pathway, it is found that β-catenin, as a key molecule in Wnt signal transduction pathway, is closely associated to the incidence of HCC. Recently, more and more studies have shown that the abnormal activation of classical Wnt signal pathway plays a compelling part in the occurrence and advancement of hepatocellular carcinoma. Hepatocytes because of hidden onset, early rise can be no clinical symptoms, so the clinical discovery is mostly late, the mortality rate is high. At present, the clinical methods for the treatment of hepatocellular carcinoma are liver transplantation, radiotherapy and chemotherapy. However, hepatocellular carcinoma is easy to metastasize and has a high recurrence rate, so the mortality rate of hepatocellular carcinoma is still high. Wnt/β-catenin signal pathway has become major topic of debate in cancer research. In this paper, we begin with the classification of liver cancer and some pathogenic mechanisms. The effects of β-catenin protein on the occurrence, metastasis and immune regulation of hepatocellular carcinoma were also discussed. Under the background of the popular "signal transduction therapy" in recent years, to explore the therapeutic effect of targeted drugs targeting Wnt/β-catenin signal pathway in hepatocellular carcinoma. Because of the high degree of malignancy and limited treatment of hepatocellular carcinoma, we will mainly discuss the effect of Wnt signal pathway on the metastasis of hepatocellular carcinoma and its effect on the differentiation of immune cells. Abnormal activation of Wnt signaling pathway in hepatocellular carcinoma.

A demographic study on causes of hepatitis transitions among the agricultural community

Background: A better understanding of the interaction between SARS-CoV-2 infection and HBV or HCV hepatitis is very important. Objectives: We aimed to determine the prevalence and the impact of pre-existing HBV and HCV infections in patients with COVID-19. Methods: We conducted a retrospective study and included all the subjects positive for SARS-CoV-2 from March to May 2020. We evaluated the prevalence of chronic HBV and HCV infections and performed a matched cohort analysis to compare COVID-19-related outcomes between patients with and without infections due to HBV or HCV. Results: Among 606 subjects, 12 cases (2%) had positive HBsAg, and 6 cases (0.99%) presented detectable HCV RNA. We recognized 80 individuals positive for SARS-CoV-2 with negative markers for HBV and HCV suitable for the matched analysis. No statistical differences in mechanical ventilation support and mortality rates were found (P = 0.27 and P = 0.80, respectively). Moreover, although not statistically different, individuals with viral hepatitis were more likely to be admitted to the Intensive Care Unit in comparison to those without HBV or HCV infections (29% vs. 15%). The median time of virus clearance was 27.5 days, with no difference between the two groups. Conclusions: In our cohort, the pre-existing viral liver infection did not have any impact on the clinical and virological evolution of COVID-19.

BackgroundHCV‐related extra‐hepatic complications include peripheral neuropathies, with important prevalence and impact. A recent metanalysis of previous intervention trials concluded for insufficient data to support evidence‐based treatments for this complication. In this longitudinal study, we assessed for the first time prevalence and outcome of neuropathy in a cohort of patients with chronic HCV, before and after direct‐acting antiviral agent (DAA) treatment.MethodNinety‐four patients (mean age 58.5 ± 9.9, infection duration 22.2 ± 6.3 years) without systemic and metabolic diseases, underwent neurological examination and electroneurography studies before (T0) and 10.4 ± 1.7 months after the end of DAA therapy (T1), and cryoglobulins (CG) assessment. Muscle strength was evaluated by Medical Research Council (MRC) score; neuropathic pain, sensory function, disability, quality of life were assessed by validated questionnaires (DN4, NPSI, SSS, INCAT and Euro‐QoL).ResultsAt T0, sensory‐motor neuropathy was detected in 22 patients (23%), reflexes were depressed in 32 (34%) with no association with infection duration, viral load, age, CG. Neuropathic pain (DN4 ≥4) was present in 37 patients (39%). At T1, out of the 22 patients with altered electroneurography, 3 had died or developed HCC, 4 showed normal electroneurography, and nerve amplitude parameters tended to improve in the whole group. Only 11 patients (12%) had depressed reflexes and 10 (11%) DN4 ≥4 (P < .05 compared to T0). Scores for MRC, questionnaires and Euro‐QoL improved significantly (P < .05).ConclusionOur study confirms the high prevalence of clinical and subclinical peripheral sensory‐motor neuropathy in patients with HCV infection and indicates improvement after eradication by DAA. These results support the need for larger intervention studies.

Background and aims. For the 8-week OPrD regimen, real world data are insufficient. This study aims to compare the efficacy of the two types of regimens (12-week versus 8-week) in a real world cohort of patients with genotype 1b. Material and methods. We analysed a multicentric retrospective cohort enrolling 1436 patients who started HCV therapy in 2018-2019. Liver fibrosis was staged in all subjects by Fibromax. Efficacy was assessed by the percentage of patients achieving SVR 12 weeks post-treatment (SVR12). Results. Out of the 1436 analysed patients, 112 received 8 weeks therapy and 1324 received 12 weeks. In this cohort the proportion of male patients was 25.2%, the median age 61 years, 28.2% were interferon pre-treated, and the rate of co-morbidities was 47%. 42% of the subjects had F2 fibrosis, 29% F1 fibrosis, 16% F3 and 12% F4. The SVR rate was comparable in both groups of patients (97% in those treated with OPrD 12 weeks vs 96.4% in those that received OPrD 8 weeks) (by intention-to-treat). In the 12 weeks arm, the drop-out rate was 0.8% and the rate of severe adverse events was 1%, while in the arm of 8 weeks therapy there were no severe adverse events reported and no drop-out (p = 0.25). The only predictive factor for non-response in both treatment arms was the male sex. Conclusions. OPrD 8 weeks proved to be highly efficient in our patients with a 96.4% SVR. No serious adverse events and no drop out were reported.

Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients